Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines

01-Jun-2007

Nobilon and Vivalis announced that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.

The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include an upfront payment, milestone payments and royalties.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance